Literature DB >> 10754779

Follicular development and hormonal levels following highly purified or recombinant follicle-stimulating hormone administration in ovulatory women undergoing ovarian stimulation after pituitary suppression for in vitro fertilization: implications for implantation potential.

J Balasch1, F Fábregues, M Creus, J Peñarrubia, E Vidal, F Carmona, B Puerto, J A Vanrell.   

Abstract

PURPOSE: The main goal in the present study was to compare follicular development and estradiol levels after ovarian stimulation in pituitary suppressed normally ovulating women undergoing IVF, using highly purified urinary follicle stimulating hormone (FSH) (u-FSH-HP) and recombinant FSH (rec-FSH). A secondary variable in our study was embryo implantation potential, which is closely related to appropriate follicular development and oocyte competence.
METHODS: For the main purpose of this study, 30 IVF patients (group 1) were treated during IVF consecutive cycles, using the same stimulation protocol, with u-FSH-HP in the first treatment study cycle and rec-FSH in the second one. As a control group (group 2) for implantation rates obtained in cycles treated with rec-FSH, 30 additional IVF patients were included who underwent a second IVF attempt again with u-FSH-HP.
RESULTS: The total dose of FSH used and ovarian response obtained in terms of estradiol plasma levels and the total number of growing follicles on the day of human chronic gonadotropin (HCG) injection were similar in both treatment cycles in group 1 but better follicular dynamics and oocyte maturity were obtained with rec-FSH. The implantation rate was significantly higher in rec-FSH treated cycles in patients in group 1 than in control women (group 2).
CONCLUSIONS: rec-FSH is more efficacious than u-FSH-HP when used in the same patient in inducing multiple follicular development in down-regulated cycles as indicated by ovarian performance and oocyte maturity. In addition, rec-FSH yields significantly higher implantation rates than u-FSH-HP when used in patients undergoing their second IVF attempt.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10754779      PMCID: PMC3455196          DOI: 10.1023/a:1009493829086

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  24 in total

Review 1.  Ovarian markers of implantation potential in assisted reproduction.

Authors:  L Gregory
Journal:  Hum Reprod       Date:  1998-12       Impact factor: 6.918

2.  A comparison of in vitro fertilization results after embryo transfer after 2, 3, and 4 days of embryo culture.

Authors:  G J Huisman; A T Alberda; R A Leerentveld; A Verhoeff; G H Zeilmaker
Journal:  Fertil Steril       Date:  1994-05       Impact factor: 7.329

Review 3.  Current concepts of the roles of follicle stimulating hormone and luteinizing hormone in folliculogenesis.

Authors:  S G Hillier
Journal:  Hum Reprod       Date:  1994-02       Impact factor: 6.918

4.  The follicle-stimulating hormone threshold level for follicle maturation in superovulated cycles.

Authors:  D E Lolis; O Tsolas; I E Messinis
Journal:  Fertil Steril       Date:  1995-06       Impact factor: 7.329

Review 5.  Pharmacokinetics of follicle-stimulating hormone: clinical significance.

Authors:  Z Ben-Rafael; T Levy; J Schoemaker
Journal:  Fertil Steril       Date:  1995-04       Impact factor: 7.329

6.  Clinical pharmacology of recombinant human follicle-stimulating hormone. III. Pharmacokinetic-pharmacodynamic modeling after repeated subcutaneous administration.

Authors:  H C Porchet; J Y le Cotonnec; E Loumaye
Journal:  Fertil Steril       Date:  1994-04       Impact factor: 7.329

7.  Accumulation of human chorionic gonadotrophin in the serum of patients during in-vitro fertilization treatment cycles with Pergonal.

Authors:  M Rodgers; J McLoughlin; N Peers; J Anderson; P Woods; G G Mitchell; W R Robertson
Journal:  Hum Reprod       Date:  1994-04       Impact factor: 6.918

8.  Use of follicle-stimulating hormone alone (urofollitropin) to stimulate the ovaries for assisted conception after pituitary desensitization.

Authors:  M G Hull; R J Armatage; A McDermott
Journal:  Fertil Steril       Date:  1994-11       Impact factor: 7.329

9.  Stimulation of ovarian follicular maturation with pure follicle-stimulating hormone in women with gonadotropin deficiency.

Authors:  B Couzinet; N Lestrat; S Brailly; M Forest; G Schaison
Journal:  J Clin Endocrinol Metab       Date:  1988-03       Impact factor: 5.958

10.  Results of ovulation induction using human menopausal gonadotropin or purified follicle-stimulating hormone in hypogonadotropic hypogonadism patients.

Authors:  Z Shoham; A Balen; A Patel; H S Jacobs
Journal:  Fertil Steril       Date:  1991-12       Impact factor: 7.329

View more
  4 in total

1.  Reflections on the cost-effectiveness of recombinant FSH in assisted reproduction. The clinician's perspective.

Authors:  J Balasch; P N Barri
Journal:  J Assist Reprod Genet       Date:  2001-02       Impact factor: 3.412

2.  Cost-effectiveness of recombinant versus urinary follicle-stimulating hormone in assisted reproduction techniques in the Spanish public health care system.

Authors:  Alberto Romeu; Juan Balasch; José A Ruiz Balda; Pedro N Barri; Salim Daya; Jean P Auray; Gerald Duru; Ariel Beresniak; José A Peinado
Journal:  J Assist Reprod Genet       Date:  2003-08       Impact factor: 3.412

3.  Recombinant human follicle-stimulating hormone for ovulation induction in polycystic ovary syndrome: a prospective, randomized trial of two starting doses in a chronic low-dose step-up protocol.

Authors:  J Balasch; F Fábregues; M Creus; R Casamitjana; B Puerto; J A Vanrell
Journal:  J Assist Reprod Genet       Date:  2000-11       Impact factor: 3.412

4.  Success of frozen embryo transfer: Does the type of gonadotropin influence the outcome?

Authors:  Hesham Al-Inany; Pieter van Gelder
Journal:  Int J Womens Health       Date:  2010-08-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.